NCT07256392Phase 3Enrolling by invitation

Long-term Efficacy and Safety Extension (LTE) Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria

Study sponsor: Celldex Therapeutics

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2028-09Estimated
Enrollment · participants1370Estimated
Source updated2026-11-02Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 1 field changed

Recruitment status changed

Before: Recruiting. After: Enrolling by invitation.

Check registry source

· 1 field changed

Recruitment status changed

Before: Not yet recruiting. After: Recruiting.

Check registry source